PMID- 23880594
OWN - NLM
STAT- MEDLINE
DCOM- 20140624
LR  - 20151119
IS  - 1878-1780 (Electronic)
IS  - 1262-3636 (Linking)
VI  - 39
IP  - 5
DP  - 2013 Oct
TI  - Avoidance of weight gain is important for oral type 2 diabetes treatments in 
      Sweden and Germany: patient preferences.
PG  - 397-403
LID - S1262-3636(13)00125-0 [pii]
LID - 10.1016/j.diabet.2013.06.001 [doi]
AB  - AIMS: The aim of the study was to quantify patient preferences for outcomes 
      associated with oral antidiabetic medications (OAMs) in Sweden and Germany 
      through a discrete-choice experiment. METHODS: Adults taking OAMs who had a 
      self-reported physician's diagnosis of type 2 diabetes mellitus (T2DM) made a 
      series of nine choices between pairs of hypothetical profiles. Each profile had a 
      predefined range of attributes: blood glucose control, frequency of 
      mild-to-moderate hypoglycaemia, annual severe hypoglycaemic events, annual weight 
      gain, pill burden and frequency of administration, and cost. Choice questions 
      were based on an experimental design with known statistical properties. Bivariate 
      probit analysis estimated the probabilities of choice of medication 
      administration from patient characteristics and, conditional on that choice, 
      preferences for treatment outcomes. RESULTS: The final sample consisted of 188 
      Swedish and 195 German patients. For both countries, weight gain was the most 
      important attribute, followed by blood glucose control. Avoiding a 5-kg weight 
      gain was 1.5 times more important in Sweden and 2.3 times more important in 
      Germany than achieving moderate blood glucose control, thereby, suggesting that 
      blood glucose control is relatively more important to Swedish than to German 
      patients. Least important outcomes were the number of daily pills (Sweden) and 
      frequency of mild-to-moderate hypoglycaemia (Germany). CONCLUSION: Patients in 
      both Sweden and Germany preferred OAMs not associated with weight gain.
CI  - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
FAU - Mohamed, A F
AU  - Mohamed AF
AD  - RTI Health Solutions, 200 Park Offices Drive, Research Triangle Park, NC, USA.
FAU - Zhang, J
AU  - Zhang J
FAU - Johnson, F R
AU  - Johnson FR
FAU - Lomon, I Duprat
AU  - Lomon ID
FAU - Malvolti, E
AU  - Malvolti E
FAU - Townsend, R
AU  - Townsend R
FAU - Ostgren, C J
AU  - Ostgren CJ
FAU - Parhofer, K G
AU  - Parhofer KG
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20130720
PL  - France
TA  - Diabetes Metab
JT  - Diabetes & metabolism
JID - 9607599
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Administration, Oral
MH  - Blood Glucose/*metabolism
MH  - Choice Behavior
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/*drug therapy/epidemiology
MH  - Diabetic Angiopathies/epidemiology/etiology/*prevention & control
MH  - Female
MH  - Germany/epidemiology
MH  - Humans
MH  - Hypoglycemia/chemically induced
MH  - Hypoglycemic Agents/*administration & dosage/adverse effects
MH  - Male
MH  - Medication Adherence
MH  - Middle Aged
MH  - Patient Preference
MH  - Self Care
MH  - Surveys and Questionnaires
MH  - Sweden/epidemiology
MH  - Treatment Outcome
MH  - Weight Gain/*drug effects
OTO - NOTNLM
OT  - Analyse conjointe
OT  - Choice-format conjoint analysis
OT  - Discrete-choice experiment
OT  - Oral antidiabetic medication
OT  - Patient preferences
OT  - Preferences des patients
OT  - Traitements antidiabetiques oraux
EDAT- 2013/07/25 06:00
MHDA- 2014/06/25 06:00
CRDT- 2013/07/25 06:00
PHST- 2013/02/13 00:00 [received]
PHST- 2013/06/03 00:00 [revised]
PHST- 2013/06/04 00:00 [accepted]
PHST- 2013/07/25 06:00 [entrez]
PHST- 2013/07/25 06:00 [pubmed]
PHST- 2014/06/25 06:00 [medline]
AID - S1262-3636(13)00125-0 [pii]
AID - 10.1016/j.diabet.2013.06.001 [doi]
PST - ppublish
SO  - Diabetes Metab. 2013 Oct;39(5):397-403. doi: 10.1016/j.diabet.2013.06.001. Epub 
      2013 Jul 20.